Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy.
Cancer Res Commun. 2022 Nov 29;2(11):1504-1519. doi: 10.1158/2767-9764.CRC-22-0151. eCollection 2022 Nov.
Cancer Res Commun. 2022.
PMID: 36970050
Free PMC article.
Tumor vasculature is regulated by FGF/FGFR signaling-mediated angiogenesis and bone marrow-derived cell recruitment: this mechanism is inhibited by SSR128129E, the first allosteric antagonist of FGFRs.
Fons P, Gueguen-Dorbes G, Herault JP, Geronimi F, Tuyaret J, Frédérique D, Schaeffer P, Volle-Challier C, Herbert JM, Bono F.
Fons P, et al. Among authors: gueguen dorbes g.
J Cell Physiol. 2015 Jan;230(1):43-51. doi: 10.1002/jcp.24656.
J Cell Physiol. 2015.
PMID: 24760775
Item in Clipboard
SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities.
Alam A, Blanc I, Gueguen-Dorbes G, Duclos O, Bonnin J, Barron P, Laplace MC, Morin G, Gaujarengues F, Dol F, Hérault JP, Schaeffer P, Savi P, Bono F.
Alam A, et al. Among authors: gueguen dorbes g.
Mol Cancer Ther. 2012 Aug;11(8):1637-49. doi: 10.1158/1535-7163.MCT-11-0866-T. Epub 2012 May 14.
Mol Cancer Ther. 2012.
PMID: 22584122
Item in Clipboard
Cite
Cite